Jennifer L. Brooks

Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P ₁ ) and receptor‐5 (S1P ₅ ) agonist with autoimmune disease‐modifying activity

Fiona L. Scott, Bryan Clemons, Jennifer L. Brooks et al. · British Journal of Pharmacology · 2016 · 305 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Structure−Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase

Anne B. Eldrup, Charles Allerson, C. Frank Bennett et al. · Journal of Medicinal Chemistry · 2004 · 187 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Structure−Activity Relationship of Heterobase-Modified 2‘-<i>C</i>-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication

Anne B. Eldrup, Marija Prhavc, Jennifer L. Brooks et al. · Journal of Medicinal Chemistry · 2004 · 186 citations

Pharmacy, Biochemistry, Pharmacology +17

The Pleckstrin Homology Domain in Insulin Receptor Substrate-1 Sensitizes Insulin Signaling

Martin G. Myers, Timothy C. Grammer, Jennifer L. Brooks et al. · Journal of Biological Chemistry · 1995 · 115 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach et al. · The Journal of Clinical Pharmacology · 2017 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15